Association between rates of ischemic stroke and all-cause mortality with the Watchman device compared to warfarin and direct oral anticoagulants in patients with atrial fibrillation
CONCLUSION: While DOACs were associated with lower ischemic stroke rates, treatment with the Watchman device was associated with lower all-cause mortality. Patients placed on the Watchman device due to DOAC contraindications may benefit from its lower all-cause mortality risk.PMID:38174006 | PMC:PMC10761157 | DOI:10.1080/08998280.2023.2269354 (Source: Baylor University Medical Center Proceedings)
Source: Baylor University Medical Center Proceedings - January 4, 2024 Category: Universities & Medical Training Authors: Bright Etumuse Brittany Miles Source Type: research
Factors Associated With Oral Anticoagulant Use in Patients With Atrial Fibrillation and Mental Disorders
Conclusions: An OAC treatment gap for AF patients with comorbid SMI relative to other mental illnesses was identified. The gap was wider in those with dependence comorbidities, positive symptoms, self-injury, or functional impairment.J Clin Psychiatry 2024;85(1):23m14824.Author affiliations are listed at the end of this article.PMID:38175946 | DOI:10.4088/JCP.23m14824 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - January 4, 2024 Category: Psychiatry Authors: Dina Farran Matthew Broadbent Aikaterini Dima Mark Ashworth Fiona Gaughran Source Type: research
Association between rates of ischemic stroke and all-cause mortality with the Watchman device compared to warfarin and direct oral anticoagulants in patients with atrial fibrillation
CONCLUSION: While DOACs were associated with lower ischemic stroke rates, treatment with the Watchman device was associated with lower all-cause mortality. Patients placed on the Watchman device due to DOAC contraindications may benefit from its lower all-cause mortality risk.PMID:38174006 | PMC:PMC10761157 | DOI:10.1080/08998280.2023.2269354 (Source: Baylor University Medical Center Proceedings)
Source: Baylor University Medical Center Proceedings - January 4, 2024 Category: Universities & Medical Training Authors: Bright Etumuse Brittany Miles Source Type: research
Factors Associated With Oral Anticoagulant Use in Patients With Atrial Fibrillation and Mental Disorders
Conclusions: An OAC treatment gap for AF patients with comorbid SMI relative to other mental illnesses was identified. The gap was wider in those with dependence comorbidities, positive symptoms, self-injury, or functional impairment.J Clin Psychiatry 2024;85(1):23m14824.Author affiliations are listed at the end of this article.PMID:38175946 | DOI:10.4088/JCP.23m14824 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - January 4, 2024 Category: Psychiatry Authors: Dina Farran Matthew Broadbent Aikaterini Dima Mark Ashworth Fiona Gaughran Source Type: research
Association between rates of ischemic stroke and all-cause mortality with the Watchman device compared to warfarin and direct oral anticoagulants in patients with atrial fibrillation
CONCLUSION: While DOACs were associated with lower ischemic stroke rates, treatment with the Watchman device was associated with lower all-cause mortality. Patients placed on the Watchman device due to DOAC contraindications may benefit from its lower all-cause mortality risk.PMID:38174006 | PMC:PMC10761157 | DOI:10.1080/08998280.2023.2269354 (Source: Baylor University Medical Center Proceedings)
Source: Baylor University Medical Center Proceedings - January 4, 2024 Category: Universities & Medical Training Authors: Bright Etumuse Brittany Miles Source Type: research
Factors Associated With Oral Anticoagulant Use in Patients With Atrial Fibrillation and Mental Disorders
Conclusions: An OAC treatment gap for AF patients with comorbid SMI relative to other mental illnesses was identified. The gap was wider in those with dependence comorbidities, positive symptoms, self-injury, or functional impairment.J Clin Psychiatry 2024;85(1):23m14824.Author affiliations are listed at the end of this article.PMID:38175946 | DOI:10.4088/JCP.23m14824 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - January 4, 2024 Category: Psychiatry Authors: Dina Farran Matthew Broadbent Aikaterini Dima Mark Ashworth Fiona Gaughran Source Type: research
Edoxaban Anticoagulation in Atrial Fibrillation: Real-World Data and Evidence
This article provides an overview of real-world evidence regarding edoxaban's use in preventing stroke and systemic embolic events in AF patients, emphasizing the concerns that physicians factor into their clinical decision-making.PMID:38164780 | DOI:10.5543/tkda.2023.73869 (Source: Turk Kardiyoloji Dernegi arsivi)
Source: Turk Kardiyoloji Dernegi arsivi - January 2, 2024 Category: Cardiology Authors: Serkan Çay Mithat Kasap Source Type: research
Edoxaban Anticoagulation in Atrial Fibrillation: Real-World Data and Evidence
This article provides an overview of real-world evidence regarding edoxaban's use in preventing stroke and systemic embolic events in AF patients, emphasizing the concerns that physicians factor into their clinical decision-making.PMID:38164780 | DOI:10.5543/tkda.2023.73869 (Source: Turk Kardiyoloji Dernegi arsivi)
Source: Turk Kardiyoloji Dernegi arsivi - January 2, 2024 Category: Cardiology Authors: Serkan Çay Mithat Kasap Source Type: research
Edoxaban Anticoagulation in Atrial Fibrillation: Real-World Data and Evidence
This article provides an overview of real-world evidence regarding edoxaban's use in preventing stroke and systemic embolic events in AF patients, emphasizing the concerns that physicians factor into their clinical decision-making.PMID:38164780 | DOI:10.5543/tkda.2023.73869 (Source: Turk Kardiyoloji Dernegi arsivi)
Source: Turk Kardiyoloji Dernegi arsivi - January 2, 2024 Category: Cardiology Authors: Serkan Çay Mithat Kasap Source Type: research
Edoxaban Anticoagulation in Atrial Fibrillation: Real-World Data and Evidence
This article provides an overview of real-world evidence regarding edoxaban's use in preventing stroke and systemic embolic events in AF patients, emphasizing the concerns that physicians factor into their clinical decision-making.PMID:38164780 | DOI:10.5543/tkda.2023.73869 (Source: Turk Kardiyoloji Dernegi arsivi)
Source: Turk Kardiyoloji Dernegi arsivi - January 2, 2024 Category: Cardiology Authors: Serkan Çay Mithat Kasap Source Type: research
Edoxaban Anticoagulation in Atrial Fibrillation: Real-World Data and Evidence
This article provides an overview of real-world evidence regarding edoxaban's use in preventing stroke and systemic embolic events in AF patients, emphasizing the concerns that physicians factor into their clinical decision-making.PMID:38164780 | DOI:10.5543/tkda.2023.73869 (Source: Turk Kardiyoloji Dernegi arsivi)
Source: Turk Kardiyoloji Dernegi arsivi - January 2, 2024 Category: Cardiology Authors: Serkan Çay Mithat Kasap Source Type: research
Edoxaban Anticoagulation in Atrial Fibrillation: Real-World Data and Evidence
This article provides an overview of real-world evidence regarding edoxaban's use in preventing stroke and systemic embolic events in AF patients, emphasizing the concerns that physicians factor into their clinical decision-making.PMID:38164780 | DOI:10.5543/tkda.2023.73869 (Source: Turk Kardiyoloji Dernegi arsivi)
Source: Turk Kardiyoloji Dernegi arsivi - January 2, 2024 Category: Cardiology Authors: Serkan Çay Mithat Kasap Source Type: research
Comparison Of Pharmacist-directed And Protocol-driven Warfarin Management In Ambulatory Patients With Left Ventricular Assist Device
Management of advanced heart failure patients with a left ventricular assist device (LVAD) improves survival and quality of life. Patients with an LVAD require anticoagulation with warfarin for thrombosis prevention. Complications observed include both bleeding and thrombotic events (BE and TE, respectively). Median time in therapeutic range (TTR) reported in clinical studies for other disease states is 65%. Limited studies have evaluated warfarin management in the outpatient setting for patients with an LVAD. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Dusty Lisi, Ryan Martin Tags: 047 Source Type: research
Warfarin Vs. Direct Oral Anticoagulants For Left Ventricle Thrombus Treatment
Left ventricular thrombus (LVT) is a feared complication of LV dysfunction associated with acute myocardial infarction (MI) and heart failure (HF). Currently warfarin is the standard of care for the treatment of LVT. Direct oral anticoagulants (DOACs) are increasingly used as alternatives to warfarin for the treatment of LVT. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Waseem Farooq, Raheel Khan, Ronak Bahuva, Matthew Kaye, Ali Mir, Gregory Gudleski, Brian Page Tags: 235 Source Type: research
